Oric Pharmaceuticals, Inc. ORIC
13.16
(0.02)
(0.15%)
as of 25 Sep
- Market cap
- $1.4B
- P/E
- 0.0×
Follow ORIC
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| ROE | (39.80%) | (42.57%) | (41.27%) | (39.73%) |
+8 more TTM periods Free account |
| ROA | (37.35%) | (39.79%) | (37.91%) | (36.90%) | |
| ROIC | (83.77%) | (70.11%) | (86.88%) | (77.24%) | |
| Return on Tangible Assets | (55.00%) | (49.24%) | (47.87%) | (48.66%) | |
| Free Cash Flow per Share | (1.04) | (1.05) | (1.27) | (1.18) | |
| Free Cash Flow | (112.26) | (111.20) | (111.68) | (117.24) | |
| Capital Expenditures | (0.62) | (0.33) | (0.71) | (0.70) | |
| Other line items | |||||
| Cash ROIC | (17.28%) | (15.90%) | (16.67%) | (16.79%) | |
| Accounts Payable Turnover | 0.00 | 0.00 | 0.00 | 0.00 | |
| Average Days of Payables | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | |
| Research and Development Expense of Revenue | 0.00% | 0.00% | 0.00% | 0.00% | |
| Selling, General and Administrative Expense of Revenue | 0.00% | 0.00% | 0.00% | 0.00% | |
| Share Based Compensation of Revenue | 0.00% | 0.00% | 0.00% | 0.00% | |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating CF/Net income | 0.80 | 0.82 | 0.86 | 0.86 | |
| Depreciation/Fixed assets | 0.34 | (0.03) | (0.45) | (0.97) | |
| Capex/Depreciation | (0.81) | 4.81 | 0.66 | 0.28 | |
| Revenue per Share | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating CF per Share | (1.03) | (1.05) | (1.26) | (1.18) | |
| Capex per Share | (0.01) | 0.00 | (0.01) | (0.01) | |
| Capex to Sales | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates